2380:HKEXNDFOS Co., Ltd. Analysis
Data as of 2026-03-07 - not real-time
₩2,890.00
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Technical snapshot: NDFOS is trading close to its 52‑week high with a regular market price of 2,890 KRW, while the RSI sits at an elevated 79, signaling an overbought condition. The MACD remains bullish, the histogram is positive, and volume is on an upward trend, suggesting short‑term buying pressure despite a neutral overall trend direction. However, the 30‑day volatility is exceptionally high at roughly 88%, and the computed beta of 0.37 points to limited correlation with broader market moves, adding a layer of price instability.
Fundamental backdrop: The company posted a revenue growth of about 11% year‑over‑year and maintains a respectable gross margin near 38%, yet it recorded a negative profit margin and a ROE of –10%, reflecting earnings challenges. Cash reserves exceed 23 billion KRW while debt stands at 6.5 billion KRW, resulting in a high debt‑to‑equity ratio. Most strikingly, the discounted cash‑flow model assigns a fair value of over 10,000 KRW, implying the stock is deeply undervalued relative to its current price. No dividend is paid, so income‑oriented investors have little appeal. The combination of strong cash, revenue momentum, and a massive valuation gap supports a longer‑term upside thesis, albeit tempered by short‑term price overextension.
Fundamental backdrop: The company posted a revenue growth of about 11% year‑over‑year and maintains a respectable gross margin near 38%, yet it recorded a negative profit margin and a ROE of –10%, reflecting earnings challenges. Cash reserves exceed 23 billion KRW while debt stands at 6.5 billion KRW, resulting in a high debt‑to‑equity ratio. Most strikingly, the discounted cash‑flow model assigns a fair value of over 10,000 KRW, implying the stock is deeply undervalued relative to its current price. No dividend is paid, so income‑oriented investors have little appeal. The combination of strong cash, revenue momentum, and a massive valuation gap supports a longer‑term upside thesis, albeit tempered by short‑term price overextension.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- RSI in overbought territory
- Bullish MACD but neutral trend
- Proximity to 52‑week resistance
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF valuation gap (fair value > current price)
- Strong cash position versus modest debt
- Revenue growth exceeding 10% annually
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Structural undervaluation offering upside potential
- Potential earnings turnaround as margins improve
- Stable sector demand for specialty chemicals
Key Metrics & Analysis
Financial Health
Revenue Growth10.90%
Profit Margin-26.07%
ROE-10.73%
ROA1.86%
Debt/Equity6.70
Op. Cash Flow₩15.0B
Free Cash Flow₩9.6B
Technical Analysis
TrendNeutral
RSI79.2
Support₩1,538.00
Resistance₩3,015.00
MA 20₩1,922.90
MA 50₩1,853.02
MA 200₩1,918.37
MACDBullish
VolumeIncreasing
Fear & Greed Index68.77
Valuation
Fair Value₩10,009.32
Target Price₩0.00
GradeUndervalued
TypeGrowth
Risk Assessment
Beta0.37
Volatility88.04%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.